SecBot SecBot

TOVX drug pipeline

Theriva Biologics, Inc. · 3 rated drugs
$0.1400
0.0% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 bullish · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 2b completed; Phase 2a (VIRAGE2) authorized/enrolling; Phase 3 design aligned with FDA and EMA
Time to marketLikely 4-6 years if Phase 3 is successful, assuming the company secures funding/partnership to initiate a pivotal trial

VCN-01 zabilugene almadenorepvec Updated Jul 7

What to watch

VCN-01 is the only meaningful asset at a ~$10M market-cap company. The positive VIRAGE Phase 2b data and FDA/EMA alignment on Phase 3 design are real positives, but the company has only ~$14M cash (runway into Q1 2027) and needs a partnership or dilutive financing to fund the pivotal trial. Watch for partnership/licensing announcements and VIRAGE2 interim data as the next catalysts, the stock is highly binary and prone to large swings.

Bull case
  • Virally delivered mechanism works differently from targeted therapies, degrades tumor stroma and works in all-comers regardless of KRAS mutation status, making it potentially complementary rather than directly competitive with RAS inhibitors like daraxonrasib
  • Phase 2b VIRAGE trial met primary endpoints with compelling data: median OS 10.8 vs 8.6 months, 56% reduction in death risk, and even stronger benefit with two doses (data presented at ESMO 2025 and AACR 2026)
  • FDA and EMA both provided positive guidance on Phase 3 trial design after End-of-Phase 2 meetings, rare dual regulatory alignment that de-risks the path forward
Bear case
  • Company is severely cash-constrained: only $14.4M cash as of March 2026 (runway into Q1 2027), already cut 32% of workforce in Sept 2025, and has no disclosed path to fund a costly Phase 3 pivotal trial without dilutive financing or partnership
  • Revolution Medicines' daraxonrasib (RMC-6236) produced stunning Phase 3 results nearly doubling OS in ~500 KRAS-mutant PDAC patients, this is a potential competitor covering ~90% of the addressable market and has already reshaped investor expectations for pancreatic cancer treatment
  • Phase 2b OS improvement (10.8 vs 8.6 months) is modest in absolute terms and the control arm (8.6 months) underperforms current real-world standards, may face higher bar in Phase 3 if RAS inhibitors enter the frontline setting
● neutral
Impact
PhasePreclinical
Time to marketNot estimable; the asset is now owned by Biossil Labs, which has not announced clinical timelines

SYN-007 ribaxamase (reformulated delayed-release) Updated Nov 2

What to watch

SYN-007 is no longer part of Theriva Biologics. The sale to Biossil Labs closed October 30, 2026. Investors should watch Theriva's Q3 2026 earnings on November 10 for cash runway details and updates on VCN-01, the company's sole remaining pipeline asset. Any future SYN-007 value to Theriva depends entirely on Biossil's ability to advance the program, over which Theriva has no control.

Bull case
  • Theriva eliminated burn on a preclinical asset it had already deprioritized, receiving $350K upfront and retaining upside via up to $91M in milestones and low single-digit royalties on any future sales.
  • SYN-007 addresses a large addressable market: oral amoxicillin/clavulanate accounted for over 70 million U.S. prescriptions per year, and protecting the gut microbiome during antibiotic treatment is a validated medical need.
Bear case
  • SYN-007 never advanced beyond preclinical (dog) studies and had no confirmed path to human trials, making the milestone/royalty upside highly speculative.
  • Theriva received only $350K upfront against a ~$9M market cap (net ~$210K after paying PREV ABR LLC) and must share 33-50% of future proceeds with PREV, capped at $13M, substantially diluting any potential upside.
  • Theriva now has zero control over SYN-007's development, which depends entirely on Biossil Labs' execution and funding priorities.
● neutral
Impact
PhasePreclinical
Time to marketUncertain; the asset is preclinical and now owned by Biossil Labs with no disclosed clinical timelines. Human trials have not yet begun.

SYN-006 Updated Nov 2

What to watch

SYN-006 was divested to Biossil Labs on October 30, 2026. For TOVX shareholders, the asset is no longer in the pipeline; the only remaining link is potential milestone payments from Biossil, which are uncertain, shared with a third party (PREV ABR), and depend on Biossil's development timeline. Monitor Biossil's progress only as a back-end value driver.

Bull case
  • SYN-006 is a novel oral carbapenemase that showed proof-of-concept in animal models for protecting the gut microbiome from carbapenem antibiotic damage, potentially reducing C. difficile infection and antibiotic resistance.
  • Biossil Labs is backed by OpenAI and Founders Fund with $70M+ in disclosed funding, giving it resources to potentially advance the asset.
  • Antibiotic resistance is a growing global health concern; if Biossil successfully develops SYN-006, it could address an unmet need and generate milestone/royalty payments for Theriva.
Bear case
  • SYN-006 never advanced beyond preclinical animal models (pig/dog); no human clinical data existed at the time of divestiture.
  • Theriva sold SYN-006 for only $350,000 upfront (net ~$210,000 after the PREV ABR payment), indicating limited perceived value.
  • The milestone payments (up to $3M regulatory, $88M sales) are highly speculative; Theriva must share 33-50% of them with PREV ABR LLC.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Nab-paclitaxelStudy of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic CancerPhase 2Completed · results112Mar 28, 2025